JAMA Neurology is a leading peer-reviewed journal published by the American Medical Association, focused on advancing the understanding and treatment of neurological disorders. With an impressive impact factor and ranked in the 99th percentile among clinical neurology journals, this publication is recognized as Q1 in its category for 2023, highlighting its significance in the field. Since its inception, the journal has provided a platform for high-quality research, clinical trials, and reviews that inform both clinicians and researchers. Operating from its headquarters in Chicago, Illinois, JAMA Neurology offers rich insights into the latest advancements in neurology, featuring articles that span a wide range of topics including neurodegenerative diseases, stroke, epilepsy, and neurocritical care. Researchers and professionals are encouraged to access the journal’s content freely, as it employs open access options to promote the dissemination of critical knowledge. As a critical resource in the field of neurology, JAMA Neurology is essential for anyone involved in this dynamic and rapidly evolving specialty.

NEUROPEDIATRICS is a prominent academic journal published by GEORG THIEME VERLAG KG, dedicated to advancing the understanding and treatment of neurological disorders in children. Established in 1980, this journal has consistently provided a platform for innovative research and clinical practice in the fields of pediatrics and neurology, culminating in its recognition across various rankings; it holds a Q2 rating in Pediatrics, Perinatology and Child Health, and Q3 in both Medicine (miscellaneous) and Neurology (clinical) as of 2023. While NEUROPEDIATRICS is not an open access journal, it remains a crucial resource for researchers, clinicians, and students who seek cutting-edge insights and evidence-based practices in the management of pediatric neurological issues. As a result, NEUROPEDIATRICS plays an indispensable role in shaping future research directions and improving health outcomes in this vital field.

Neurology and Therapy, published by SPRINGER LONDON LTD, stands as a pivotal platform for researchers and practitioners in the field of neurology and its therapeutic applications. This Open Access journal, active since 2012, facilitates the dissemination of innovative studies and cutting-edge findings aimed at improving neurological health. With an impressive ranking in the 2023 Scopus Rankings, where it holds a Q2 category in Neurology and a Q1 category in Clinical Neurology, it underscores its prominence in advancing neurological research. The journal's intriguing scope encompasses a wide-ranging exploration of neurological disorders, treatment methodologies, and healthcare strategies, making it a valuable resource for those vested in enhancing patient outcomes. With an appealing average impact factor, readers are encouraged to dive into the latest advancements and engage with the scholarly discussions that are shaping the future of neurology.

SEIZURE - EUROPEAN JOURNAL OF EPILEPSY is a leading journal published by W B SAUNDERS CO LTD, specializing in the field of epilepsy and seizure disorders. Since its inception in 1992, this journal has committed itself to advancing research and understanding in neurology, achieving a respectable 2023 impact factor reflected by its Q2 rankings in Medicine (miscellaneous), Neurology, and Clinical Neurology categories. With an impressive Scopus ranking that places it in the top 35% of journals in Neuroscience and Neurology, SEIZURE is dedicated to promoting high-quality research and clinical studies that offer insights into epilepsy management and treatment. Although not an open-access journal, it maintains a diverse array of original articles, reviews, and case studies catering to academicians, medical professionals, and students looking to expand their knowledge on epilepsy. This journal is pivotal for those seeking to stay abreast of the latest trends, therapies, and findings in the neuroclinical landscape.

Journal of Bone Oncology, published by ELSEVIER, is a pivotal open access journal that has been advancing the field of oncology since its inception in 2012. Focused on the intricate relationship between bone-related malignancies and therapeutic advancements, this journal addresses critical issues in bone oncology, including novel treatments, diagnostic methodologies, and translational research. With a commendable impact factor reflecting its scholarly contributions and ranking in the Q2 category of oncology journals (2023), the Journal of Bone Oncology is recognized within the top 67th percentile across Scopus rankings, showcasing its relevance and quality in the medical oncology landscape. Available in open access, the journal promotes widespread dissemination of knowledge, ensuring that researchers, professionals, and students can access groundbreaking research that informs clinical practices and enhances patient outcomes. Located in Germany and targeting a global audience, the journal’s wealth of resources serves as an essential platform for fostering collaboration and innovation in the oncology community.

CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.

Acta Epileptologica is a prominent open-access journal published by SPRINGERNATURE, dedicated to advancing research in the fields of neurology and clinical neurology. With its ISSN 2096-9384 and E-ISSN 2524-4434, this journal has established itself as a key resource for researchers and practitioners worldwide, particularly since its transition to open access in 2019. Based in the United Kingdom, Acta Epileptologica aims to disseminate high-quality research and foster scholarly collaboration, as evidenced by its consistent Q3 ranking in both neurology and clinical neurology categories as of 2023. Although currently positioned in the lower percentiles on Scopus, the journal plays a critical role in exploring emerging trends and novel therapeutic approaches in epilepsy research, making it an essential platform for academics, healthcare professionals, and students deeply invested in the evolving landscape of neurological disorders.

EPILEPSY & BEHAVIOR is a premier journal dedicated to advancing the field of neurology and behavioral neuroscience, published by Academic Press Inc. Elsevier Science. With a focus on the complex interplay between epilepsy and behavioral disorders, this journal serves as a pivotal platform for researchers, clinicians, and educators alike. The journal holds a commendable position with a Q2 ranking in key categories such as Behavioral Neuroscience and Clinical Neurology, highlighting its influence and contributions to the scientific community. Notably, EPILEPSY & BEHAVIOR is indexed in Scopus, ranking in the top percentiles across various related fields, which underscores the quality and relevance of the research it publishes. As it navigates from its inception in 2000 to its ongoing work into 2024, the journal remains committed to disseminating high-quality research and insights that address critical issues in epilepsy and associated behavioral challenges, providing invaluable resources for ongoing education and innovation in the field.

NEUROLOGY, published by Lippincott Williams & Wilkins, stands as a premier journal in the field of neurology, holding an esteemed Q1 category ranking in clinical neurology as of 2023. Established in 1951, this journal has been a critical resource for the dissemination of cutting-edge research and clinical advancements, with an impressive Scopus rank of 24 out of 400, placing it in the 94th percentile among its peers. NEUROLOGY serves as a vital platform for neurologists, researchers, and medical professionals seeking to stay abreast of the latest findings and innovations in the treatment and understanding of neurological disorders. With its rigorous peer-review process and commitment to excellence, NEUROLOGY remains essential reading for all individuals dedicated to advancing the science and practice of neurology, contributing significantly to the ongoing dialogue in this vital area of medicine.

BRAIN & DEVELOPMENT is a prestigious academic journal published by ELSEVIER, renowned for its pivotal contributions to the fields of developmental neuroscience, neurology, and pediatrics. Established in 1979, this journal has become an essential resource for researchers and clinicians alike, as it explores the complexities of brain development and associated neurological disorders in children. With an impactful focus on advancing scientific understanding, BRAIN & DEVELOPMENT is currently ranked in the Q3 quartile in Developmental Neuroscience and Clinical Neurology and Q2 in Pediatrics, reflecting its significance within the medical community. Its ISSN 0387-7604 and E-ISSN 1872-7131 underline its established presence in academic literature. While the journal does not offer open access options, it continues to be a key platform for disseminating new research findings and fostering innovation in the understanding of pediatric neurological health. The journal's commitment to quality research is further evidenced by its ongoing publication trajectory up until 2024, making it a vital source of knowledge for students, professionals, and educators in related fields.